Vascular smooth muscle cell (VSMC) growth is a critical step in the development of restenosis and is likely an important contributor to the pathogenesis of atherosclerosis, although its role in the latter needs to be established. The objective of this proposal will be to systematically define and compare the effects of insulin resistance, hyperinsulinemia, diabetes, and angiotensin II on the development of both intimal hyperplasia (balloon angioplasty in the rat) and VSMC growth in atherosclerosis (LDL receptor knockout mouse). An exciting aspect of this investigation is that we will use thiazolidinedione analogs to alter these pathologies, since we have discovered that they inhibit VSMC growth in addition to their well- known activity to enhance insulin mediated glucose uptake. This action may be due to the ability of these agents to inhibit nuclear translocation of mitogen activated protein (MAP) kinase which we will investigate. We further demonstrated that this growth inhibitory effect is relevant in vivo, since troglitazone, a member of the thiazolidinedione family, inhibited VSMC intimal hyperplasia in the rat aortic injury model. These novel analogs will now allow us to elucidate the importance of VSMC growth ina the atherosclerotic process and the critical cellular signal transduction mechanisms mediating growth in VSMC.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
7R01HL058328-02
Application #
2460239
Study Section
Special Emphasis Panel (ZHL1-CSR-Y)
Project Start
1996-09-15
Project End
2001-07-31
Budget Start
1997-09-30
Budget End
1998-07-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Ogawa, Daisuke; Stone, Jeffrey F; Takata, Yasunori et al. (2005) Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res 96:e59-67
Blaschke, Florian; Leppanen, Olli; Takata, Yasunori et al. (2004) Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 95:e110-23
Bruemmer, Dennis; Berger, Joel P; Liu, Joey et al. (2003) A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol 466:225-34
Bruemmer, Dennis; Yin, Fen; Liu, Joey et al. (2003) Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ Res 93:e38-47
Bruemmer, Dennis; Yin, Fen; Liu, Joey et al. (2003) Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. Mol Endocrinol 17:1005-18
Bruemmer, Dennis; Yin, Fen; Liu, Joey et al. (2003) Rapamycin inhibits E2F-dependent expression of minichromosome maintenance proteins in vascular smooth muscle cells. Biochem Biophys Res Commun 303:251-8
Bruemmer, Dennis; Yin, Fen; Liu, Joey et al. (2003) Expression of minichromosome maintenance proteins in vascular smooth muscle cells is ERK/MAPK dependent. Exp Cell Res 290:28-37
Bruemmer, Dennis; Yin, Fen; Liu, Joey et al. (2003) Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. Eur J Pharmacol 462:15-23
Joseph, Sean B; McKilligin, Elaine; Pei, Liming et al. (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 99:7604-9
Kintscher, Ulrich; Lyon, Christopher; Wakino, Shu et al. (2002) PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res 91:e35-44

Showing the most recent 10 out of 30 publications